Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy
| Autor: | Björn Risberg, Marie Bixo, Doris Englund, Björn Jonsson, Inga Stina Ödmark, Sven Eric Olsson |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Patient Dropouts Biopsy animal diseases medicine.medical_treatment Blood Pressure Medroxyprogesterone Acetate Endometrium Body Mass Index Obstetrics and gynaecology Internal medicine medicine Humans Medroxyprogesterone acetate Prospective Studies Prospective cohort study Ultrasonography Gynecology Estrogens Conjugated (USP) medicine.diagnostic_test Uterine Hemorrhage business.industry Incidence (epidemiology) Estrogen Replacement Therapy Obstetrics and Gynecology Postmenopause medicine.anatomical_structure Multivariate Analysis Female Hormone therapy business medicine.drug Endometrial biopsy |
| Zdroj: | Menopause. 12:699-707 |
| ISSN: | 1072-3714 |
| Popis: | To determine compliance, the incidence of untoward effects, and endometrial safety in postmenopausal women treated with 3-month sequential hormone therapy for up to 5 years.A prospective, uncontrolled multicenter study of 129 women treated with 0.625 mg conjugated estrogens daily plus 10 mg medroxyprogesterone acetate for 14 days every third month. Endometrial biopsy samples were taken before the initiation of the study and then yearly during the next 5 years. Bleeding patterns were recorded.Upon completion of the first 12 months of treatment, 76 of 126 biopsied women (60%) had secretory endometrium. After 5 years, this finding was reversed in biopsy specimens completed by 59 women, among whom 32 (56%) had insufficient or atrophic endometrium. We did not find any hyperplasia when the biopsy specimen was taken according to the protocol. One endometrial cancer was found by biopsy after 12 months, but the subsequent hysterectomy showed no sign of cancer. Ultrasound determinations of mean endometrial thickness during therapy showed a thin endometrium (mean = 4 mm, range = 1-13 mm). Amenorrhea was reported by 6.2% of 129 women after 12 months of treatment. Among the 59 women who completed the study, 71.2% had regular bleeding patterns every third month, 25.4% reported amenorrhea, and 3.4% had irregular bleeding patterns.The addition of 10 mg of medroxyprogesterone acetate for 14 days every third month to treatment with 0.625 mg of conjugated estrogens daily was well tolerated, and was associated with high endometrial safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|